160 People Wanted to Be Buried in Space. Their Capsule Slammed Into the Ocean Instead.
A spacecraft called the Nyx capsule recently crashed in the Pacific Ocean after the landing parachutes failed to deploy.
The capsule carried cargo including cannabis and human remains, all of which were lost in the crash.
After apologizing to the families who lost their loved one's remains, the company responsible for the spacecraft said this 'partial success' should serve as an important learning opportunity for future reusable space flight missions.
As part of a rideshare mission with SpaceX, the Nyx capsule launched from the Vandenberg Space Force Base on June 23rd. The next day, after successfully re-entering the atmosphere on June 24th, the capsule crashed into the Pacific Ocean and lost some unexpected cargo: cannabis and human remains.
The Nyx capsule and its launch was part of the program 'Mission Possible' led by a German start-up called The Exploration Company (TEC). The launch marks TEC's second spacecraft to reach orbit in under four years.
Now, the cannabis plant matter and seeds weren't for recreational use—they're part of an open-source citizen science project called Martian Grow. The project seeks to understand the effect of microgravity on germination and resilience, potentially shedding light on how life could survive in non-terrestrial environments.
The human remains, however, were on the capsule for a much more... wholesome reason: to memorialize loved ones. Celestis—a Texas-based tribute company—provided ashes from over 160 deceased individuals to make the trip into space (sadly, this is not the first time Celestis lost a payload, the first being in 2023 when a rocket carrying a late NASA astronaut's ashes exploded over New Mexico).
'We apologize to all our clients who entrusted us with their payloads,' TEC wrote in a statement. 'We thank our teams for their hard work and their dedication to success. We have been pushing boundaries in record time and cost. This partial success reflects both ambition and the inherent risks of innovation. Leveraging the technical milestones achieved yesterday and the lessons we will extract from our ongoing investigation, we will then prepare to re-fly as soon as possible.'
The founder and CEO of TEC, Hélène Huby, also apologized for the lost cargo, suggesting the mission is something the space tech world can grow from.
'We all hoped for full success; partial success is often part of the road for those who take risks and push boundaries to change the world positively.' she said in a press release. 'I take full responsibility and present my apologies to our customers for not achieving full success.'
TEC explained in the press release that the spacecraft crashed because the landing parachutes failed to deploy. In the same release, the company stated the parachute system wasn't drop-tested—a risk that 'lower costs, shorten development time, and yield a deeper understanding of the vehicle with each flight,' according to TEC. The parachute model had previously been used on SpaceX's Dragon.
According to TEC, the recent setback won't stop their mission—in fact, it's only helped progress it.
'We are continuing our journey, eager to implement these learnings in our next vehicle,' Huby said in the press release. 'We will learn from Mission Possible and improve, together as a team. I express my profound gratitude to The Exploration Company's team members who are demonstrating outstanding solidarity, resilience, and commitment to the success of our mission.'
You Might Also Like
The Do's and Don'ts of Using Painter's Tape
The Best Portable BBQ Grills for Cooking Anywhere
Can a Smart Watch Prolong Your Life?
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 hours ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool
Yahoo
11 hours ago
- Yahoo
Kumail Nanjiani recalls meeting Elon Musk while shooting 'Silicon Valley':' ''He didn't like the show'
Kumail Nanjiani said that Elon Musk was "upset" with the opening scene of Silicon Valley. Nanjiani appeared on an episode of Mike Birbiglia's podcast Working It Out, where he recalled some of the experiences he had with tech giants while on the show. "He didn't like the show," Nanjiani said of Musk. The Eternals actor remembered meeting the Tesla CEO, who said the parties he attended were "much cooler" than those depicted on Silicon Valley. The premiere opens with Kid Rock playing at a tech event to a sparse, dead crowd. "It was like, 'Yeah, man. You're one of the richest people in the world. We're, like, losers on the show. Of course your parties are better than my parties. What are you talking about?'" the Big Sick star said. The comedian also met Mark Zuckerberg while doing the show, but made a bad impression. He and his costar Martin Starr had presented at the Breakthrough Awards, which were co-founded by Zuckerberg, in 2016. During the ceremony, the Silicon Valley actors called back to a joke from the season 1 finale about giving hand jobs to an entire conference room of people. They retooled that bit to accommodate the number of scientists at the Breakthrough Awards and bombed. Nanjiani said he doesn't blame the Facebook founder for disliking him after that moment. "He was like, 'What the f--- was that?'" Nanjiani said. "And truly in that moment he was right." Check out the full episode of Working It Out with Kumail Nanjiani below. Read the original article on Entertainment Weekly
Yahoo
11 hours ago
- Yahoo
High-potency cannabis use linked to psychosis
More research is showing that the use of high-potency cannabis may elevate the risk of dissociation, including schizophrenia. Nivrita Ganguly speaks with Dr. Leslie Buckley, Chief of Addictions at the Centre for Addiction and Mental Health (CAMH) about what is known and not known about the link between cannabis and psychosis.
